S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:BNOX

Bionomics - BNOX Stock Forecast, Price & News

$4.28
-0.12 (-2.73%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.02
$5.33
50-Day Range
$3.80
$7.24
52-Week Range
$3.51
$12.99
Volume
40,453 shs
Average Volume
10,605 shs
Market Capitalization
$34.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Bionomics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
239.2% Upside
$14.50 Price Target
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Bionomics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.54) to ($3.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

837th out of 1,049 stocks

Pharmaceutical Preparations Industry

409th out of 514 stocks


BNOX stock logo

About Bionomics (NASDAQ:BNOX) Stock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNOX Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
BNOX.OQ - | Stock Price & Latest News | Reuters
Bionomics Ltd. ADR
Squawk Box
Quarterly Activities Report for June 2022
6 Stocks Halted In Wednesday's Session
Bionomics Ltd ADR (BNOX)
Bionomics Limited Rings the Closing Bell
BNOX.OQ - Bionomics Ltd Profile | Reuters
See More Headlines
Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

BNOX Company Calendar

Today
1/29/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNOX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.50
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+239.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$7.38 per share

Miscellaneous

Free Float
8,038,000
Market Cap
$34.88 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Adrian Hinton BEC (Age 71)
    F.C.A., Acting Chief Financial Officer
    Comp: $223.12k
  • Mr. Connor Bernstein M.Sc. (Age 35)
    VP of Strategy & Corp. Devel.
    Comp: $237.72k
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Sec.













BNOX Stock - Frequently Asked Questions

Should I buy or sell Bionomics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNOX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNOX, but not buy additional shares or sell existing shares.
View BNOX analyst ratings
or view top-rated stocks.

What is Bionomics' stock price forecast for 2023?

3 equities research analysts have issued 1 year target prices for Bionomics' shares. Their BNOX share price forecasts range from $6.00 to $23.00. On average, they predict the company's share price to reach $14.50 in the next year. This suggests a possible upside of 239.2% from the stock's current price.
View analysts price targets for BNOX
or view top-rated stocks among Wall Street analysts.

How have BNOX shares performed in 2023?

Bionomics' stock was trading at $4.65 at the start of the year. Since then, BNOX shares have decreased by 8.1% and is now trading at $4.2750.
View the best growth stocks for 2023 here
.

When did Bionomics IPO?

(BNOX) raised $20 million in an initial public offering on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

What is Bionomics' stock symbol?

Bionomics trades on the NASDAQ under the ticker symbol "BNOX."

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionomics' stock price today?

One share of BNOX stock can currently be purchased for approximately $4.28.

How much money does Bionomics make?

Bionomics (NASDAQ:BNOX) has a market capitalization of $34.88 million and generates $260,000.00 in revenue each year.

How can I contact Bionomics?

Bionomics' mailing address is 31 Dalgleish St, Thebarton, South Australia 5031. The official website for the company is www.bionomics.com.au. The company can be reached via phone at 61 8 8354 6100 or via email at investorrelations@bionomics.com.

This page (NASDAQ:BNOX) was last updated on 1/29/2023 by MarketBeat.com Staff